Shiva Pharmachem Ltd IPO Details
Shiva Pharmachem was originally incorporated on March 18, 1999. They are a manufacturer of acid and alkyl chlorides.
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 0 | - | - | ₹9,000.0 M | DRHP DOC |
Shiva Pharmachem Ltd issue details
Shiva Pharmachem Ltd IPO issue size is ₹ 9,000.0 M
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
Shiva Pharmachem Ltd IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
Shiva Pharmachem Ltd NUMBER OF SHARES ON OFFER
Shiva Pharmachem Ltd FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| FY23 | 1,053.7 | 10,794.7 | 1,412.5 | 15.1 | 18.9% |
| FY22 | 892.7 | 10,159.9 | 778.3 | -342.6 | 15.7% |
| FY21 | 851.2 | 7,601.2 | 1,866.6 | 288.1 | 18.5% |
Shiva Pharmachem Ltd INFORMATION ON IPO ISSUE
About Shiva Pharmachem Ltd
Shiva Pharmachem was originally incorporated on March 18, 1999. They are a manufacturer of acid and alkyl chlorides.
Object of the Issue
- Carry out an offer for sale aggregating up to Rs 900 crore by the selling shareholders.
- Achieve the benefits of listing the equity shares on the stock exchanges.
Shiva Pharmachem Ltd - PROMOTERS
| Name |
|---|
| Rakesh Shiwebhagwan Agrawal |
| Vishal Rakesh Agrawal |
| Rahul Rakesh Agrawal |
Shiva Pharmachem Ltd Book running lead manager
JM Financial Limited
shiva.pharmachem@jmfl.com
Kotak Mahindra Capital Company Limited
shivapharma.ipo@kotak.com
Shiva Pharmachem Ltd Registrar to the offer
Link Intime India Private Limited
shivapharmachem.ipo@linkintime.co.in
Shiva Pharmachem Ltd Strengths
Leading player
The company has over 20 years of experience in the Indian specialty chemicals business and is focused on large-scale manufacturing of acid and alkyl chlorides, as well as advanced intermediates involving complex chemistry and multi-step processes
Diversified, global customer base
Its customer base includes 181 multinational and domestic companies. In Fiscal 2023, over 80% of its revenue from operations was generated from Fortune 500 companies globally
Strategically located manufacturing facilities
The company's manufacturing infrastructure, advanced technologies, logistics, and inventory management are key growth drivers for the business. Its manufacturing in India and Hungary, coupled with an international storage network, offer cost and speed of delivery benefits to its customers
Shiva Pharmachem Ltd Risks
Concentrated revenue stream
It derives a significant portion (more than 60%) of its revenue from operations from its top 10 customers, with the single largest customer contributing more than 18% of revenue from operations in fiscal 2023
Dependent on sales outside of India
It is dependent on sales outside of India, which accounted for a significant portion (more than 70%) of revenue from operations in each of the last three fiscal years. The demand for products outside India is subject to international market conditions and foreign regulatory risks
Regulatory compliances
It has received closure notices in the past from the Gujarat Pollution Control Board for its manufacturing facilities at Luna and Dahej SEZ in Gujarat
IPO FAQs
The promoters of the company are Rakesh Shiwebhagwan Agrawal, Vishal Rakesh Agrawal and Rahul Rakesh Agrawal.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.